Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MPLT vs ELWT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ELWT Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 4–4 Matrix Metrics)

ELWT Overall Winner 6-Pillar Tally: MPLT 2 – 4 ELWT Matrix Metrics: MPLT 4 – 4 ELWT

As of Nov 20, 2026, ELWT (ELWT) is the stronger overall head-to-head candidate over MapLight Therapeutics, Inc. (MPLT) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). MPLT carries a Unified Composite Score of 48.3/100 (HOLD) at $5.94 (N/M Forward P/E, 0.0% operating margin), whereas ELWT carries 51.7/100 (HOLD) at $2.97 (N/M Forward P/E, -55.0% operating margin).

  • Technical & Structure Timing Caution: MPLT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.2); meanwhile ELWT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MPLT vs ELWT
MPLT US Equity
MapLight Therapeutics, Inc.
Pharmaceutical Preparations
$5.94
-7.48% 1D
Market Cap $356.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.19β · 79% Vol
Unified Composite Score
48.3 / 100 HOLD
Tech 33.0 Fund 64.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.4%), weak momentum, RSI 30
RSI-14: 30.2 · SMA20: $7.08 · SMA50: $8.63
ELWT US Equity Head-to-Head Winner
ELWT
Institutional Equity
$2.97
-2.94% 1D
Market Cap $20.3M
TTM Revenue $19M
Forward P/E N/M
Beta / 30D Vol 1.20β · 88% Vol
Unified Composite Score
51.7 / 100 HOLD
Tech 60.0 Fund 52.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.6%), weak momentum, RSI 23
RSI-14: 23.3 · SMA20: $3.83 · SMA50: $5.37

6-Pillar Scorecard Institutional Category Breakdown (MPLT 2 – 4 ELWT)

Columns: Metric · MPLT · ELWT
1. Valuation Multiples ELWT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 1.1x
2. Growth & Scale ELWT
Revenue Growth (YoY) +0.0% +6.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $19M
Market Cap $356.8M $20.3M
3. Profitability & Quality MPLT
Gross Margin N/A 10.0%
Operating Margin 0.0% -55.0%
Net Profit Margin 0.0% -55.6%
Return on Equity (ROE) -74.2% 0.0%
4. Balance Sheet & Cash Flow MPLT
Cash Generation (TTM) -$179M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $54M Net Cash 0.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ELWT
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 97.5% (9th %ile) N/A (N/A)
Put/Call OI Skew 1.67x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ELWT
OpEx & R&D Intensity N/A 65.0% of Rev ($12M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Telecom Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MPLT (4) vs ELWT (4)
Institutional Metric MPLT ELWT Criterion Row Edge
Market Capitalization
Scale
$356.8M $20.3M Larger Scale MPLT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +6.6% Higher Growth ELWT
Operating Margin (TTM)
Profitability
0.0% -55.0% Higher Margin MPLT
Net Profit Margin
Profitability
0.0% -55.6% Higher Margin MPLT
Return on Equity (ROE)
Capital Efficiency
-74.2% 0.0% Higher ROE ELWT
52-Week Range Position
Momentum
0% ($6–$40) 5% ($3–$10) Stronger Trend ELWT
Beta / 30D Volatility
Risk Regime
1.19β · 79% Vol 1.20β · 88% Vol Lower Realized Risk MPLT
Unified Institutional Score
Composite Signal
48.3 / 100 (HOLD) 51.7 / 100 (HOLD) Higher Composite ELWT
Trailing 12M Revenue (USD)
Operating Scale
N/A $19M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 10.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$179M ($54M Net Cash) N/A (0.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MPLT +16.95 pp
MPLT: -28.0% · ELWT: -44.95%
3M Horizon MPLT +9.4 pp
MPLT: -51.11% · ELWT: -60.51%
6M Horizon ELWT +15.42 pp
MPLT: -78.06% · ELWT: -62.64%
1Y Horizon MPLT +1.08 pp
MPLT: -59.32% · ELWT: -60.4%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MPLT vs ELWT. Trailing 12-month operating profitability (MPLT 0.0% vs ELWT -55.0%) and valuation multiples (MPLT N/M vs ELWT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MPLT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-74.2% · N/M
ELWT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$19M
Gross Margin10.0%
Op. Margin-55.0%
ROE / Fwd P/E0.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MPLT BREAKDOWN
148d in phase · OBV DISTRIBUTION
Current IV 97.5%
IV Percentile 9th %ile
Put/Call OI Skew 1.67x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact MPLT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ELWT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ELWT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MPLT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $356.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ELWT Moat Profile Cyclical / Execution-Driven Positioning
Telecom Services Operator
Competes within the Telecom Services value chain with $20.3M market capitalization and -55.0% operating margin.
OpEx & R&D Reinvestment 65.0% of Rev ($12M)
90D Engineering Disclosures 0 Published

Investor FAQ MPLT vs ELWT Key Questions & Quantitative Answers

As of Nov 20, 2026, ELWT (ELWT) is the stronger overall head-to-head candidate over MapLight Therapeutics, Inc. (MPLT) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). MPLT carries a Unified Composite Score of 48.3/100 (HOLD) at $5.94 (N/M Forward P/E, 0.0% operating margin), whereas ELWT carries 51.7/100 (HOLD) at $2.97 (N/M Forward P/E, -55.0% operating margin). Technical & Structure Timing Caution: MPLT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.2); meanwhile ELWT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ELWT leads the Growth & Scale pillar: MPLT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ELWT at +6.6% YoY revenue growth and +0.0% YoY earnings growth on $19M TTM revenue (10.0% gross margin, -55.0% operating margin). On trailing 12-month operating scale, MPLT generates N/A in USD-normalized revenue versus $19M for ELWT. In operating R&D and SG&A reinvestment, MPLT deploys N/A (0 90-day corporate R&D disclosures) versus 65.0% of Rev ($12M) (0 disclosures) for ELWT.

ELWT screens cheaper on headline valuation multiples. MPLT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ELWT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MPLT (-74.2% ROE) versus ELWT (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, MPLT carries 97.5% implied volatility (9th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.19β · 79% Vol realized risk). By comparison, ELWT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.20β · 88% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.